Updating results

884 results

Sort: Relevance | Date

Sotagliflozin, in combination with insulin, for treating type 1 diabetes [ID1376]

In development [GID-TA10376] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

In development [GID-TA10186] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: TBC

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: TBC

Technology appraisal guidance In development

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: 18 November 2020

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Avelumab for untreated PD-L1 positive non-small-cell lung cancer [ID1261]

In development [GID-TA10250] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab for multiple myeloma [ID966]

In development [GID-TA10134] Expected publication date: TBC

Technology appraisal guidance In development

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

In development [GID-TA10565] Expected publication date: TBC

Technology appraisal guidance In development

Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

In development [GID-TA10607] Expected publication date: TBC

Technology appraisal guidance In development

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

In development [GID-TA10608] Expected publication date: TBC

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]

In development [GID-TA10181] Expected publication date: TBC

Technology appraisal guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: TBC

Technology appraisal guidance In development

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [ID1521]

In development [GID-TA10471] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma [ID2708]

In development [GID-TA10588] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Venetoclax for treating chronic lymphocytic leukaemia (TA487)

Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published November 2017

Aflibercept for treating choroidal neovascularisation (TA486)

Evidence-based recommendations on aflibercept (Eylea) for treating myopic choroidal neovascularisation in adults

Technology appraisal guidance Published November 2017

Sarilumab for moderate to severe rheumatoid arthritis (TA485)

Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults

Technology appraisal guidance Published November 2017

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

Technology appraisal guidance Published November 2017

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

Technology appraisal guidance Published November 2017

Immunosuppressive therapy for kidney transplant in children and young people (TA482)

Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people

Technology appraisal guidance Published October 2017

Immunosuppressive therapy for kidney transplant in adults (TA481)

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults

Technology appraisal guidance Published October 2017

Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis (rheumatism) in adults

Technology appraisal guidance Published October 2017

Reslizumab for treating severe eosinophilic asthma (TA479)

Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults

Technology appraisal guidance Published October 2017

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

Technology appraisal guidance Published October 2017

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

Technology appraisal guidance Published October 2017

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults

Technology appraisal guidance Published September 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab

Technology appraisal guidance Published August 2017

Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults

Technology appraisal guidance Published August 2017

Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary

Technology appraisal guidance Published September 2002 Last updated March 2010

Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)

NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence

Technology appraisal guidance Published August 2017

Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults

Technology appraisal guidance Published June 2018

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published June 2018

Midostaurin for untreated acute myeloid leukaemia (TA523)

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published June 2018

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer (NSCLC) after chemotherapy in adults

Technology appraisal guidance Published May 2018

Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

Technology appraisal guidance Published October 2002

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Technology appraisal guidance Published April 2018

Tocilizumab for treating giant cell arteritis (TA518)

Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults

Technology appraisal guidance Published April 2018